In vivo measurements of tumor metabolism and growth after administration of nzastaurin using small animal FDG positron emission tomography

Michael Lahn, Karen Pollok, Nathan Enas, Ann McNulty, Jeremy Graff, Shanbao Cai, Jennifer R. Hartwell, Aaron Ernstberger, Donald Thornton, Les Brail, Gary Hutchins

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background. The use of 2-[ 18 F ]fluoro-2-deoxy-D-glucose ([ 18 F ]FDG) may help to establish the antitumor activity of enzastaurin, a novel protein kinase C-beta II (PKC- II) inhibitor, in mouse xenografts. Methods. The hematologic cell line RAJI and the solid tumor cell line U87MG were each implanted in NOD/SCID mice. Standard tumor growth measurements and [ 18 F ]FDG PET imaging were performed weekly for up to three weeks after tumor implantation and growth. Results. Concomitant with caliper measurements, [ 18 F ]FDG PET imaging was performed to monitor glucose metabolism. Heterogeneity of glucose uptake in various areas of the tumors was observed after vehicle or enzastaurin treatment. This heterogeneity may limit the use of [ 18 F ]FDG PET imaging to measure enzastaurin-associated changes in xenograft tumors. Conclusion. [ 18 F ]FDG PET imaging technique does not correlate with standard caliper assessments in xenografts to assess the antitumor activity of enzastaurin. Future studies are needed to determine the use of [ 18 F ]FDG PET imaging in preclinical models.

Original languageEnglish
Article number596560
JournalJournal of Oncology
DOIs
StatePublished - 2009

Fingerprint

Positron-Emission Tomography
Heterografts
Growth
Neoplasms
Protein Kinase C beta
Glucose
Inbred NOD Mouse
SCID Mice
Deoxyglucose
Tumor Cell Line
Cell Line
enzastaurin

ASJC Scopus subject areas

  • Oncology

Cite this

In vivo measurements of tumor metabolism and growth after administration of nzastaurin using small animal FDG positron emission tomography. / Lahn, Michael; Pollok, Karen; Enas, Nathan; McNulty, Ann; Graff, Jeremy; Cai, Shanbao; Hartwell, Jennifer R.; Ernstberger, Aaron; Thornton, Donald; Brail, Les; Hutchins, Gary.

In: Journal of Oncology, 2009.

Research output: Contribution to journalArticle

Lahn, Michael ; Pollok, Karen ; Enas, Nathan ; McNulty, Ann ; Graff, Jeremy ; Cai, Shanbao ; Hartwell, Jennifer R. ; Ernstberger, Aaron ; Thornton, Donald ; Brail, Les ; Hutchins, Gary. / In vivo measurements of tumor metabolism and growth after administration of nzastaurin using small animal FDG positron emission tomography. In: Journal of Oncology. 2009.
@article{d92812c03cf9476f95ed86b12a43604b,
title = "In vivo measurements of tumor metabolism and growth after administration of nzastaurin using small animal FDG positron emission tomography",
abstract = "Background. The use of 2-[ 18 F ]fluoro-2-deoxy-D-glucose ([ 18 F ]FDG) may help to establish the antitumor activity of enzastaurin, a novel protein kinase C-beta II (PKC- II) inhibitor, in mouse xenografts. Methods. The hematologic cell line RAJI and the solid tumor cell line U87MG were each implanted in NOD/SCID mice. Standard tumor growth measurements and [ 18 F ]FDG PET imaging were performed weekly for up to three weeks after tumor implantation and growth. Results. Concomitant with caliper measurements, [ 18 F ]FDG PET imaging was performed to monitor glucose metabolism. Heterogeneity of glucose uptake in various areas of the tumors was observed after vehicle or enzastaurin treatment. This heterogeneity may limit the use of [ 18 F ]FDG PET imaging to measure enzastaurin-associated changes in xenograft tumors. Conclusion. [ 18 F ]FDG PET imaging technique does not correlate with standard caliper assessments in xenografts to assess the antitumor activity of enzastaurin. Future studies are needed to determine the use of [ 18 F ]FDG PET imaging in preclinical models.",
author = "Michael Lahn and Karen Pollok and Nathan Enas and Ann McNulty and Jeremy Graff and Shanbao Cai and Hartwell, {Jennifer R.} and Aaron Ernstberger and Donald Thornton and Les Brail and Gary Hutchins",
year = "2009",
doi = "10.1155/2009/596560",
language = "English",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - In vivo measurements of tumor metabolism and growth after administration of nzastaurin using small animal FDG positron emission tomography

AU - Lahn, Michael

AU - Pollok, Karen

AU - Enas, Nathan

AU - McNulty, Ann

AU - Graff, Jeremy

AU - Cai, Shanbao

AU - Hartwell, Jennifer R.

AU - Ernstberger, Aaron

AU - Thornton, Donald

AU - Brail, Les

AU - Hutchins, Gary

PY - 2009

Y1 - 2009

N2 - Background. The use of 2-[ 18 F ]fluoro-2-deoxy-D-glucose ([ 18 F ]FDG) may help to establish the antitumor activity of enzastaurin, a novel protein kinase C-beta II (PKC- II) inhibitor, in mouse xenografts. Methods. The hematologic cell line RAJI and the solid tumor cell line U87MG were each implanted in NOD/SCID mice. Standard tumor growth measurements and [ 18 F ]FDG PET imaging were performed weekly for up to three weeks after tumor implantation and growth. Results. Concomitant with caliper measurements, [ 18 F ]FDG PET imaging was performed to monitor glucose metabolism. Heterogeneity of glucose uptake in various areas of the tumors was observed after vehicle or enzastaurin treatment. This heterogeneity may limit the use of [ 18 F ]FDG PET imaging to measure enzastaurin-associated changes in xenograft tumors. Conclusion. [ 18 F ]FDG PET imaging technique does not correlate with standard caliper assessments in xenografts to assess the antitumor activity of enzastaurin. Future studies are needed to determine the use of [ 18 F ]FDG PET imaging in preclinical models.

AB - Background. The use of 2-[ 18 F ]fluoro-2-deoxy-D-glucose ([ 18 F ]FDG) may help to establish the antitumor activity of enzastaurin, a novel protein kinase C-beta II (PKC- II) inhibitor, in mouse xenografts. Methods. The hematologic cell line RAJI and the solid tumor cell line U87MG were each implanted in NOD/SCID mice. Standard tumor growth measurements and [ 18 F ]FDG PET imaging were performed weekly for up to three weeks after tumor implantation and growth. Results. Concomitant with caliper measurements, [ 18 F ]FDG PET imaging was performed to monitor glucose metabolism. Heterogeneity of glucose uptake in various areas of the tumors was observed after vehicle or enzastaurin treatment. This heterogeneity may limit the use of [ 18 F ]FDG PET imaging to measure enzastaurin-associated changes in xenograft tumors. Conclusion. [ 18 F ]FDG PET imaging technique does not correlate with standard caliper assessments in xenografts to assess the antitumor activity of enzastaurin. Future studies are needed to determine the use of [ 18 F ]FDG PET imaging in preclinical models.

UR - http://www.scopus.com/inward/record.url?scp=66949165546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949165546&partnerID=8YFLogxK

U2 - 10.1155/2009/596560

DO - 10.1155/2009/596560

M3 - Article

C2 - 19503801

AN - SCOPUS:66949165546

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 596560

ER -